Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-08
2008-01-08
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S238800
Reexamination Certificate
active
07317011
ABSTRACT:
Disclosed herein are methods of treating an individual suffering from peripheral neuropathy. The methods generally include administration of a therapeutic amount of optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof. Embodiments of these methods can diminish adverse side effects.
REFERENCES:
patent: 4229449 (1980-10-01), Melloni et al.
patent: 4596807 (1986-06-01), Crosby
patent: 5068433 (1991-11-01), Melloni et al.
patent: 5192751 (1993-03-01), Thor
patent: 5281624 (1994-01-01), Gehlert et al.
patent: 5391735 (1995-02-01), Melloni et al.
patent: 5441985 (1995-08-01), Foreman
patent: 5744474 (1998-04-01), Thor
patent: 5922914 (1999-07-01), Gage et al.
patent: 5998430 (1999-12-01), Schwantes et al.
patent: 6028070 (2000-02-01), Heiligenstein
patent: 6046193 (2000-04-01), Heiligenstein
patent: 6066643 (2000-05-01), Perry
patent: 6290986 (2001-09-01), Murdock et al.
patent: 6331571 (2001-12-01), Jerussi et al.
patent: 6465458 (2002-10-01), Wong et al.
patent: 6479074 (2002-11-01), Murdock et al.
patent: 6572880 (2003-06-01), Murdock et al.
patent: 6610690 (2003-08-01), Wong et al.
patent: 6642235 (2003-11-01), Wong et al.
patent: 2002/0061910 (2002-05-01), Wong et al.
patent: 2002/0107249 (2002-08-01), Wong et al.
patent: 2003/0040464 (2003-02-01), Wong et al.
patent: 2014981 (1979-09-01), None
patent: 2167407 (1988-05-01), None
patent: WO 96/12485 (1996-05-01), None
patent: WO 97/35584 (1997-10-01), None
patent: WO 97/35586 (1997-10-01), None
patent: WO 98/46227 (1998-10-01), None
patent: WO 99/09980 (1999-03-01), None
patent: WO 99/11208 (1999-03-01), None
patent: WO 99/15163 (1999-04-01), None
patent: WO 99/15176 (1999-04-01), None
patent: WO 99/15177 (1999-04-01), None
patent: WO 99/20279 (1999-04-01), None
patent: WO 99/52518 (1999-10-01), None
patent: WO 99/52531 (1999-10-01), None
patent: WO 99/58130 (1999-11-01), None
patent: WO 00/00120 (2000-01-01), None
patent: WO 01/26623 (2001-04-01), None
patent: WO 01/47503 (2001-07-01), None
patent: WO 01/62236 (2001-08-01), None
Harrison's Principle of Internal Medicine, 8thedition, vol. 2, (1997) p. 1806.
“Peripheral Neuropathy”, Robert W. Shields, Jr., published Feb. 9, 2004, www.clevelandclinicmeded.com.
“Diagnosis of Peripheral Neuropathies”, Ira Chang, CNI Review, 2002, vol. 13, No. 2.
“Peripheral Neuropathy”, Nov. 1, 2005, MayoClinic.com.
“Peripheral Neuropathy”, Julia Barrett, Gale Encyclopedia of Medicine, 1999.
“NINDS Peripheral Neuropathy Information Page”, 2006, www.ninds.nih.gov.
“Question and Answer”, ARCH FAM MED, vol. 7, 1998, pp. 470-471.
“Diabetic Neuropathy”, Dana L. Rowett, 2004, www.health.yahoo.com.
“Peripheral Neuroathy”, England et al., The Lancet, vol. 363, 2004, pp. 2151-2161.
JAMA, Nov. 11, 1998, vol. 280, No. 18 pp. 1590-1595.
“Management of Daibetic Peripheral Neuropathic Pain”, Santillan, R. M., Business Briefing: North American Pharmacotherapy, 2005, pp. 53-55.
“Diabetic Peripheral Neuropathy: Current Concepts and Treatment”, Sternberg, T. L., 2005, Northeast Florida Medicine, www.DCMS online.org, pp. 23-26.
J.J. Schildkraut, The Catecholamine Hypothesis of Affective Disorders: A Review of Supporting Evidence, Am. J. of Psychiatry, vol. 122, pp. 509-522 (Nov. 1965).
T.H. Svensson, et al., Feedback Inhibition of Brain Noradrenaline Neurons by Tricyclic Antidepressants: a-Receptor Mediation, Science, vol. 202, pp. 1089-1091 (1984).
E. Richelson et al., Blockade by Antidepressants and Related Compounds of Biogenic Amine Uptake into Rat Brain Synaptosomes: Most Antidepressants Selectively Block Norepinephrine Uptake, Europ. J of Pharmacology, vol. 104 pp. 277-286 (1984).
C.B. Nemeroff, The Neurobiology of Depression, Scientific American (1988) (8 pages).
M. Riva et al., Effect of Reboxetine, A New Antidepressant Drug, on the Central Noradrenergic System: Behavioral and Biochemical Studies, J. Drug Dev., vol. 1, No. 4, pp. 243-253 (1989).
T. Pacholczyk et al., Expression Cloning of a Cocaine-and Antidepressant-Sensitive Human Noradrenaline Transporter, Nature, vol. 350, No. 28, pp. 350-356 (Mar. 1991).
M. Max et al., Efficacy of Desipramine in Painful Diabetic Neuropathy: A Placebo-Controlled Trial, Pain, vol. 45, pp. 3-9 (1991).
E. Richelson, Biological Basis of Depression and Therapeutic Relevance, J. Clin. Psychiatry, vol. 52, No. 6 Suppl., pp. 4-10 (Jun. 1991).
M. Max et al., Effects of Desipramine Amitriptyline and Fluoxetine on Pain in Diabetic Neuropathy, New Engl. J. Med., vol. 326, No. 19, pp. 1250-1256 (1992).
B. Cusack et al., Binding Antidepressants to Human Brain Receptors: Focus on Newer Generation Compounds, Psychopharmacology, vol. 114, pp. 559-565 (1994).
M. Max, “Treatment of Post-Herpetic Neuralgia: Antidepressants,” Ann. Neurol., vol. 35, Suppl., pp. s50-s53 (1994).
W. Reimann et al., “Inhibition of Spinal Noradrenaline Uptake in Rats by the Centrally Acting Analgesic Tramadol,” Biochem. Pharmacol., vol. 47, No. 12, pp. 2289-2293 (1994).
C. Pellizzoni et al., Pharmacokinetics of Reboxetine in Healthy Volunteers. Single Against Repeated Oral Doses and Lack of Enzymatic Alterations, Biopharm. Drug Dispos. vol. 17, No. 7, pp. 623-633 (1996).
R.J. Baldessarini, Depression and Mania, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9thEd., Chapter 19, pp. 431-439, (1996).
B.E. Leonard, Noradrenaline in Basic Models of Depression, European Neuropsychopharmacology, vol. 7, Suppl. 1, pp. S11-S16 (1997).
Discussion, European Neuropsychopharmacology, vol. 7, Suppl. 1, pp. S71-S73 (1997).
S.A. Montgomery, Is There a Role For a Pure Noradrenergic Drug in the Treatment of Depression?, Eur. Neuropsychopharmacology, vol. 7, Suppl. 1, pp. S3-S9 (1997).
S.A. Montgomery, Reboxetine: Additional Benefits to the Depressed Patient, J. Psychopharmacology (Oxf), 11:4 Abstract (1997).
I. Hindmarch, The Effects of Antidepressants on Psychomotor Function With Particular Reference to Reboxetine, Eur. Neuropsychopharmacology, Vo. 7, Suppl. 1, pp. S17-S21 (1997).
E. Frigerio et al., Pharmacokinetics of Reboxetine Enantiomers in the Dog, Chirality, vol. 9, pp. 303-306 (1997).
A. Frazer, Pharmacology of Antidepressants, J. Clinical Psychopharmacology, vol. 17, No. 2, Suppl. 1, pp. 2S-18S (1997).
B. E. Leonard, The Role of Noradrenaline in Depression: a Review, J. Psychopharmacology, vol. II, No. 4 Suppl., pp. S39-S47 (1997).
Dostert et al., Review of the Pharmacokinetics and Metabolism of Reboxetine, a Selective Noradrenaline Reuptake Inhibitor, Euro. Neuropsychopharmacol., vol. 7, Suppl. 1, pp. s23-s35 (1997).
M. Owens et al., “Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites,” J. Pharmacol. Exp. Ther., vol. 283, pp. 1305-1322 (1997).
D. Healy et al., The Clinical Pharmacologic Profile of Reboxetine: Does it Involve the Putative Neurobiological Substrate of Wellbeing?, J. of Affective Disorders, vol. 51, pp. 313-322 (1998).
Anonymous, Reboxetine—Another New Antidepressant, Drugs and Therapeutics Bull., 36 (11) (1998).
S.A. Montgomery, The Place of Reboxetine in Antidepressant Therapy, J. of Clinical Psychiatry, vol. 59, Suppl. 14, pp. 26-29 (1998).
G.D. Burrows et al., Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review, J. Clin. Psychiatry, vol. 59, Suppl. 14, 4 pages (1998).
J. Massana, Reboxetine Versus Fluoxetine: An Overview of Efficacy and Tolerability, J. Clin. Psychiatry, vol. 59, Suppl 14. pp. 8-10 (1998).
A. Harkin et al., Activity and Onset of Action of Reboxetine and Effect of Combination With Sertraline in an Animal Model of Depression, Eur. J. of Pharmacology, pp. 1-10 (1998).
J. Massana et al., Reboxetine: A Double-Blind Comparison With Fluoxetine in Major Depressive Disorder, Int. Clin. Psychopharmacol, vol. 14, No. 2, pp. 73-80 (1999).
J.C. Fleishaker et al., Absolute Bioavailability of Reboxetine Enantiomers and Effect of Gender on Pharmacokinetics, Biopharm
Ahmed Saeeduddin
Marshall Robert Clyde
McArthur Robert
Taylor Duncan P.
Wong Erik H. F.
Kwon Brian
Pharmacia & Upjohn
Polster, II Philip B.
LandOfFree
Method of treating peripheral neuropathy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating peripheral neuropathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating peripheral neuropathy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2795582